Iron Deficiency Anemia Treatment Guidelines

Introduction to Iron Therapy

• The American Society of Hematology recommends that IV ferric carboxymaltose and oral iron should not be administered simultaneously as there is no clinical benefit to this combination and it may reduce the efficacy of the IV iron preparation while increasing the risk of adverse effects 1, 2, 3

Rationale for Not Combining IV and Oral Iron

• When IV iron is administered, it rapidly increases serum iron, ferritin, and transferrin saturation, making concurrent oral iron supplementation redundant 3, 4
• Oral iron absorption is regulated by hepcidin, which increases after IV iron administration, thereby blocking intestinal iron absorption and rendering oral iron ineffective 4
• Oral iron is associated with significant gastrointestinal side effects in up to 60% of patients, which would unnecessarily add to the potential side effect burden 5

Appropriate Iron Therapy Selection

• For absolute iron deficiency, the American College of Physicians recommends IV iron (preferred) or oral iron monotherapy, which should not be combined simultaneously 1, 2, 3, 4
• For functional iron deficiency, IV iron alone or IV iron with erythropoiesis-stimulating agents (ESAs) is recommended by the National Comprehensive Cancer Network 3
• Oral iron is not effective for functional iron deficiency, according to the Journal of the National Comprehensive Cancer Network 6

Administration Considerations for IV Iron

• Ferric carboxymaltose can be administered as a single high dose (up to 1000 mg) over 15 minutes, as recommended by the European Society for Clinical Nutrition and Metabolism 7
• Patients should be observed for at least 30 minutes following IV iron administration to monitor for hypersensitivity reactions, as advised by the European Society for Medical Oncology 8
• IV iron should not be administered during periods of neutropenia due to increased risk of infection (RR 1.33), according to the American Society of Hematology 1, 3
• IV iron should not be administered on the same day as anthracyclines due to theoretical risk of potentiating cardiotoxicity, as recommended by the American Society of Hematology 1, 3

Monitoring After Iron Therapy

• Iron status should be re-evaluated approximately 3 months after IV iron administration, as recommended by the European Society of Cardiology 5
• Do not check iron parameters too early after IV iron infusion as ferritin levels will be falsely elevated, according to the European Society for Clinical Nutrition and Metabolism 7

Common Pitfalls to Avoid

• Administering IV iron during active infection (contraindicated), as advised by the National Comprehensive Cancer Network 6
• Giving iron to patients with iron overload or disturbances in iron utilization, according to the European Society of Cardiology 5
• Using high-molecular weight iron dextran (Dexferrum), which has higher risk of anaphylactic reactions compared to other iron formulations including ferric carboxymaltose, as recommended by the American Society of Hematology 3, 9